These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12388634)

  • 61. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells.
    Yamaoka T; Kojima S; Ichi S; Kashiwazaki Y; Koide T; Sokawa Y
    J Interferon Cytokine Res; 1999 Dec; 19(12):1343-9. PubMed ID: 10638703
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel long-lasting interferon alpha derivatives designed by glycoengineering.
    Ceaglio N; Etcheverrigaray M; Kratje R; Oggero M
    Biochimie; 2008 Mar; 90(3):437-49. PubMed ID: 18039474
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
    Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
    Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
    Ozes ON; Reiter Z; Klein S; Blatt LM; Taylor MW
    J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 9-cis retinoic acid enhances the antiviral effect of interferon on hepatitis C virus replication through increased expression of type I interferon receptor.
    Hamamoto S; Fukuda R; Ishimura N; Rumi MA; Kazumori H; Uchida Y; Kadowaki Y; Ishihara S; Kinoshita Y
    J Lab Clin Med; 2003 Jan; 141(1):58-66. PubMed ID: 12518169
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys.
    Du Y; Tian H; Gao XD; Yao WB
    Biopharm Drug Dispos; 2008 Nov; 29(8):481-4. PubMed ID: 18985796
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.
    Fosdick A; Zheng J; Pflanz S; Frey CR; Hesselgesser J; Halcomb RL; Wolfgang G; Tumas DB
    J Pharmacol Exp Ther; 2014 Jan; 348(1):96-105. PubMed ID: 24133297
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Glucocorticoid regulation of 24-hour oscillation in interferon receptor gene expression in mouse liver.
    Koyanagi S; Suyama H; Kuramoto Y; Matsunaga N; Takane H; Soeda S; Shimeno H; Higuchi S; Ohdo S
    Endocrinology; 2006 Nov; 147(11):5034-40. PubMed ID: 16916957
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
    García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
    BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
    Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
    Kakkar T; Ma M; Zhuang Y; Patton A; Hu Z; Mounho B
    Pharm Res; 2007 Oct; 24(10):1910-8. PubMed ID: 17520181
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interferon-alpha in malignant and viral diseases. A review.
    Dorr RT
    Drugs; 1993 Feb; 45(2):177-211. PubMed ID: 7681371
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Elimination of N-glycosylation by site mutation further prolongs the half-life of IFN-α/Fc fusion proteins expressed in Pichia pastoris.
    Jia H; Guo Y; Song X; Shao C; Wu J; Ma J; Shi M; Miao Y; Li R; Wang D; Tian Z; Xiao W
    Microb Cell Fact; 2016 Dec; 15(1):209. PubMed ID: 27927205
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon.
    Walker A; Dunlevy G; Rycroft D; Topley P; Holt LJ; Herbert T; Davies M; Cook F; Holmes S; Jespers L; Herring C
    Protein Eng Des Sel; 2010 Apr; 23(4):271-8. PubMed ID: 20093262
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.
    Lopes JE; Sun L; Flick HL; Murphy EA; Losey HC
    J Pharmacol Exp Ther; 2021 Nov; 379(2):203-210. PubMed ID: 34362793
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats.
    Li H; Yang L; Cheng G; Wei HY; Zeng Q
    Arch Pharm Res; 2011 Jun; 34(6):941-8. PubMed ID: 21725815
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b.
    Qiu J; Wei XH; Geng F; Liu R; Zhang JW; Xu YH
    Acta Pharmacol Sin; 2005 Nov; 26(11):1395-401. PubMed ID: 16225764
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C.
    Subramanian GM; Fiscella M; Lamousé-Smith A; Zeuzem S; McHutchison JG
    Nat Biotechnol; 2007 Dec; 25(12):1411-9. PubMed ID: 18066038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.